Back to search results

Continuous Glucose Monitoring for Glioblastoma

This study is looking at whether using continuous glucose monitoring (CGM) can help people with glioblastoma manage their blood sugar (glucose) levels and potentially improve how long they live. Glioblastoma is a type of brain tumor, and studies suggest that high blood sugar during treatment might lead to poorer outcomes. CGM uses a small sensor under the skin to track glucose levels in real-time. You might be able to join if you are an adult (18 or older) with a new diagnosis of glioblastoma, have a good performance status (Karnofsky performance status of 70 or higher), and meet certain blood count requirements. The main goal is to see if using CGM affects how long people live after 12 months.

Study design
This interventional study plans to enroll 116 participants. It is not specified if participants will be randomly assigned to different groups.
What's involved
Participants will receive standard of care treatment, attend dietary counseling, undergo intermittent glucose monitoring, and have blood samples and MRI scans taken.
Compensation
Not stated in the trial record.
Follow-up
Overall survival will be measured at 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07091864

Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma

Recruiting
NAAges 18+InterventionalSupportive care
Mayo Clinic
~116 participants
Updated 2026-08-17 on ClinicalTrials.gov
What's tested:Best PracticeBiospecimen CollectionDietary InterventionGlucose MeasurementMagnetic Resonance ImagingMonitoring

At a glance

Recruiting sites
1 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall survival at 12 months
Measured over At 12 months

Conditions

Glioblastoma, IDH-Wildtype
WHO Grade 4 Glioma

Explore related trials

GlioblastomaIDH1 wt Allele

Where it's being run

3 sites across 3 states
Arizona1
Florida1
Minnesota1

Study leadership

  • Gelareh Zadeh, MD, PhD · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Presumed newly diagnosed GBM based on imaging findings consistent with GBM on brain MRI (e.g., heterogeneously enhancing mass with central necrosis and surrounding edema), as determined by the treating neuro-oncology team
Age ≥ 18 years at the time of consent
Negative serum pregnancy test within 7 days prior to registration for individuals of childbearing potential
Karnofsky performance status (KPS) ≥ 70 at baseline
Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L (performed within 14 days prior to registration)
Platelet count ≥ 100 × 10\^9/L (performed within 14 days prior to registration)
Hemoglobin ≥ 9 g/dL (performed within 14 days prior to registration)
Serum creatinine ≤ 1.5 × upper limit of normal (ULN) or creatinine clearance ≥ 60 mL/min (performed within 14 days prior to registration)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN (performed within 14 days prior to registration)
Total bilirubin ≤ 1.5 × ULN (performed within 14 days prior to registration)
Willingness and ability to comply with CGM device use and attend dietary counseling sessions as per standard of care

Exclusion

Recurrent glioblastoma
History of eating disorders (e.g., anorexia nervosa, bulimia) or substance use disorder within the past 12 months
Any other uncontrolled or inadequately managed medical illness (e.g., unstable cardiovascular, hepatic, renal, or psychiatric condition) that, in the opinion of the investigator, would interfere with study participation or interpretation of results
Concurrent diagnosis of another active malignancy requiring treatment
Pregnancy or breastfeeding at the time of registration
Documented history of type 1 diabetes mellitus

What this trial measures

  • Overall survival at 12 monthsAt 12 months

    Defined as the time from study enrollment until death due to any cause.